Loading clinical trials...

UNKNOWN

Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

NCT02572765•Neuromed IRCCS

Summary

The purpose of this study is to evaluate the splenic activation in hypertensive patients, as compared to normotensives, using FDG-PET/CT imaging. Moreover, the investigators will investigate whether the splenic metabolic activity relates to the expression of circulating inflammatory proteins (high-sensitivity C-reactive protein \[hsCRP\]), interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) or to immune profiles of activated T cells.

Eligibility

Age

30 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•absence of prior cancer diagnosis or remission from cancer at the time of FDG-PET/CT imaging (from at least 6 months)
•age ≥ 30 and ≤ 85 years
•absence of acute cardio/cerebrovascular disease (myocardial infarction, stroke, transient ischemic attack, revascularization)
•absence of acute or chronic inflammatory or autoimmune disease
•diagnosis of presence/absence of hypertension, on the basis of documented medical history

Exclusion Criteria

•diabetes
•atrial fibrillation
•use of anti-inflammatory drugs in the week preceding the FDG-PET/CT imaging
•chronic use of anti-inflammatory drugs

Locations (1)

IRCCS Neuromed

Pozzilli, (IS), Italy

Key Dates

Start Date

January 2, 2018

Primary Completion Date

December 1, 2022

Completion Date

September 1, 2023

Last Updated

April 11, 2022

Enrollment

120

ESTIMATED participants

Conditions

Hypertension

Interventions

PET/CT scan

OTHER

Contacts

Giuseppe Lembo, MD in Cardiology

CONTACT

+39 0865.915225 lembo@neuromed.it

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets